A new Northwestern Medicine study published in the Proceedings of the National Academy of Sciences has explored the impacts ...
As genome editing therapies move through clinical trials to regulatory approval, scientists continue the quest for the holy ...
In people with severely compromised immune systems, JC polyomavirus can trigger an untreatable, often fatal brain disease. An ...
The expanding interest in small bioactive peptides has brought renewed attention to glycyl-L-histidyl-L-lysine bound to ...
Traditional therapeutics target the inactive conformation of proteins, allowing tumors to adapt and resume signaling.
Unlike traditional proteins, its short structure allows it to act as an epigenetic modulator, potentially influencing gene ...
The mechanical process of cell division exerts powerful, if microscopic, forces. How do the molecular machines that power it ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...
A new molecular recording strategy is giving researchers a way to capture DNA–protein interactions in single cells, including the weak and transient contacts that shape gene regulation but often slip ...
A protein tied to ALS and dementia may have a much bigger role in disease than scientists realized. Researchers found that TDP43 controls a key DNA repair process, but when the protein becomes ...
Innate immunity constrains the hepatitis B virus (HBV) by sensing pathogen-associated molecular patterns (PAMPs) and inducing type I/III interferons and interferon-stimulated genes. This review ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results